NervGen Pharma Showcases at Major Growth Conference
Company Announcements

NervGen Pharma Showcases at Major Growth Conference

Story Highlights

NervGen Pharma (TSE:NGEN) has released an update.

NervGen Pharma, a biotech company focused on treating nervous system damage, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference, with President & CEO Mike Kelly presenting on August 13, 2024. Alongside the in-person event, a webcast will be available for broader access. The company continues to progress with its lead drug candidate, NVG-291, aimed at enabling nervous system repair.

For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNervGen Pharma to Present Innovative Treatments
TipRanks Canadian Auto-Generated NewsdeskNervGen Pharma Advances Spinal Injury Treatment Trial
TipRanks Canadian Auto-Generated NewsdeskNervGen Pharma Spotlights Spinal Injury Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App